T. Rowe Price Associates’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

T. Rowe Price Associates’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,226	Closed	-$423K	–	2550
2020 Q1	$423K	Sell	7,226 -535	-7%	-$52.4K	﹤0.01%	2057
2019 Q4	$981K	Sell	7,761 -351	-4%	-$47.5K	﹤0.01%	1893
2019 Q3	$993K	Sell	8,112 -2,959	-27%	-$596K	﹤0.01%	1831
2019 Q2	$3.31M	Sell	11,071 -54	-0.5%	-$22.5K	﹤0.01%	1458
2019 Q1	$5.01M	Buy	11,125 +19	+0.2%	+$8.32K	﹤0.01%	1399
2018 Q4	$5.08M	Sell	11,106 -2	-0%	-$1.24K	﹤0.01%	1404
2018 Q3	$10.1M	Sell	11,108 -5	-0%	-$3.3K	﹤0.01%	1370
2018 Q2	$6.52M	Sell	11,113 -20	-0.2%	-$13.1K	﹤0.01%	1407
2018 Q1	$7.25M	Buy	+11,133	New	+$8.36M	﹤0.01%	1381

Other funds holding HTGM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Kalos Management Alpharetta, Georgia $46.6M AUM 11.52% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

T. Rowe Price Associates's HTGM Position: Q2 2020 in Review

T. Rowe Price Associates sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q2 2020, closing a stake of 7,226 shares — an estimated $423K sold.

T. Rowe Price Associates first reported a position in HTGM in Q1 2018 and held it in 9 quarters. The position peaked at $10.1M in Q3 2018. 28 funds tracked by Wall St. Rank hold HTGM as of Q2 2020.

T. Rowe Price Associates reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
T. Rowe Price Associates sold 7,226 HTG Molecular Diagnostics, Inc. Common Stock shares in Q2 2020, an estimated $423K.
T. Rowe Price Associates first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 9 quarters.
T. Rowe Price Associates's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $10.1M in Q3 2018.
28 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q2 2020.

Based on T. Rowe Price Associates's 13F filing for Q2 2020, filed 14 Aug 2020.